AI
Sunday, June 12, 2022 9:30:19 AM
Topic: NICE Sticks it to Nissen!
On June 10, 2022, The National Institute for Health and Care Excellence (NICE, England) published the Final Draft Guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of triglycerides. https://www.nice.org.uk/search?q=icosapent
This comes after a long process of gaining Marketing Authorization Approval in the EU & UK, (921 days), and 880 days after the failure of the STRENGTH Trial, (1/14/2020). For the past two and a half years the PI of that RTC (Dr. Steve Nissen) has been on a “sour grapes” campaign to discredit the results of the REDUCE-IT trial. In that 2.5-year period the FDA, the EMA and now NICE have correctly determined that the clinical effect of the mineral oil placebo had little to do with the final outcomes.
Recent AMRN News
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
